GE Healthcare (NYSE:GE) announced today that it has acquired Zionexa and its molecular imaging agent that could enable more targeted treatment for metastatic breast cancer patients.
The financial terms of the deal were not disclosed.
Zionexa (Aubière, France) has had its FDA-approved PET imaging agent Cerianna on the U.S. market since December 2020, but it’s presently only available to a quarter of the tens of thousands of American women who have Stage 4 breast cancer. GE’s goal is to make Ceriannaaccessible to a minimum of three-quarters of patients by 2023.
“Like GE Healthcare, Zionexa’s products are aimed at enabling more precise diagnosis, improved treatment decision-making and ultimately better clinical outcomes for patients,” said Kevin O’Neill, president and CEO of GE Healthcare Pharmaceutical Diagnostics.
“This acquisition further demonstrates our commitment to enabling precision health and providing innovations that support oncologists, nuclear medicine specialists and other physicians throughout a cancer patient’s journey, from initial screening and diagnosis to informing therapy selection and monitoring the effectiveness of treatment,” O’Neill said in a news release.
Zionexa’s 24 employees in France and the U.S. will all transfer to GE Healthcare. GE will also hire about 70 more dedicated employees within the company’s U.S. Pharmaceutical Diagnostics team, headquartered in Marlborough, Mass.